Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
Sonographic Assessment in Severe Ulcerative Colitis Patients Admitted for Intravenous Corticosteroids and Eligible for Infliximab Rescue Therapy; a Prospective Clinician-blinded Observational Study Protocol.
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Copenhagen University Hospital at Herlev
- Target Recruit Count
- 50
- Registration Number
- NCT03942861
- Locations
- 🇩🇰
Herlev University Hospital, Copenhagen, Herlev, Denmark
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT03942887
- Locations
- 🇳🇱
Noordwest Ziekenhuisgroep, Alkmaar, Netherlands
🇳🇱HagaZiekenhuis, Den Haag, Netherlands
🇳🇱Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT03913559
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- C. Liam Dwyer
- Target Recruit Count
- 200
- Registration Number
- NCT03898154
- Locations
- 🇺🇸
Geisinger Woodbine, Danville, Pennsylvania, United States
Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 44
- Registration Number
- NCT03852537
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Autologous Transplant To End NMO Spectrum Disorder
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT03829566
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Veloxis de Novo Kidney Transplant ECSWD
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Simon Tremblay, PharmD, PhD
- Target Recruit Count
- 60
- Registration Number
- NCT03828682
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
Psoriatic Oligoarthritis Intervention With Symptomatic thErapy
- Conditions
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 1
- Registration Number
- NCT03797872
- Locations
- 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom
Corticosteroid Treatment in the Acute Phase of Caustic Ingestion Management
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 30
- Registration Number
- NCT03760354
Ruxolitinib and Steroid As First Line Therapy for Acute GVHD
- Conditions
- Interventions
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2024-09-30
- Target Recruit Count
- 1
- Registration Number
- NCT03701698
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.